# idiopathic pulmonary fibrosis (IPF) - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: lung tissue
- Comparison or endpoint: all-cause mortality
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d9fe74e971569d03f1ace047ce334e08d788b93d2057913b4d42b34da6d57d2f
- Response HTTP status: 200
- Prompt tokens: 118501
- Completion tokens: 49710
- Reasoning tokens: 0
- Total tokens: 168211
- API requests reported: 9
- Elapsed seconds: 705.764
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1387.824
- Question handoff seconds: 1401.194
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: DeepSeek

---
## 1. Overall biological interpretation

The uploaded survival analysis (100 unique genes, all with FDR ≤ 0.01) shows a striking directional imbalance: 93 risk-associated genes (HR > 1) versus 7 protective-associated genes (HR < 1). This asymmetry itself is informative—the prognostic transcriptome is dominated by genes whose higher expression is associated with increased all-cause mortality, rather than a balanced mix of risk and protective signals.

The dominant biological themes are:

- **Innate immune and neutrophil-driven inflammation**: S100A12, S100A14, CXCL1, CXCR1, CCL7, CD177, SELL, MMP25, PROK2, CEACAM6, CEACAM7. These genes point to neutrophil recruitment, degranulation, and chemokine signaling as risk-associated processes.
- **Epithelial injury, aberrant repair, and fibrosis-associated signaling**: SPP1, HTRA1, HGF, MET, NRG1, MUC1, KRT17, KRT23, SPRR1A, SFTPB, SFTA2, PRSS8. Multiple genes implicate alveolar epithelial stress, mucin production, and growth-factor-driven remodeling.
- **Extracellular matrix and matricellular remodeling**: EFEMP1, HTRA1, FBLIM1, DYSF, CHST15, HS3ST1, TPST1, MMP25, F5, SOD3. Genes involved in matrix turnover, sulfation, and proteolysis are enriched among risk-associated genes.
- **Metabolic reprogramming and oxidative/ferroptotic stress**: SLC7A11, SLC39A8, STEAP4, ACOX2, ALDH1A3, CYP4F3, SLC6A8. These suggest altered redox handling, iron/zinc metabolism, and lipid oxidation as risk-associated features.

The protective-associated genes (MIR221, IHH, FAM75A2, OR2M2, XLOC_003303, DYDC2, LOC100128226) are few, with several showing extreme HR values (1.9e-22) that are biologically implausible and likely reflect technical artifacts (see Limitations). The only protective gene with a more plausible effect size is LOC100128226 (HR = 0.007), a poorly annotated locus. The protective signal should therefore be interpreted with caution.

**Overall interpretation**: The prognostic transcriptome of IPF lung tissue is dominated by a coordinated risk-associated program of innate immune activation (particularly neutrophil biology), epithelial injury/aberrant repair, and matrix remodeling—processes that are all consistent with established IPF pathobiology and plausibly reflect the histopathologic heterogeneity and disease activity that drive mortality risk.

---

## 2. Core biological programs

### Program 1: Neutrophil-mediated innate immune activation and chemokine signaling
- **Direction**: Risk-associated (higher expression → worse survival)
- **Major supporting genes**: S100A12 (HR 2.53), S100A14 (HR 2.57), CXCL1 (HR 2.99), CXCR1 (HR 3.28), CCL7 (HR 3.02), CD177 (HR 2.72), SELL (HR 2.37), MMP25 (HR 3.26), PROK2 (HR 3.65)
- **Pathway**: GO: Neutrophil migration (GO:1990266); KEGG: Chemokine signaling pathway; Reactome: Neutrophil degranulation (R-HSA-6798695)
- **Explanation**: The S100 family members (S100A12, S100A14) are damage-associated molecular patterns (DAMPs) that signal through AGER (RAGE) and TLR4, driving NF-κB activation. CXCL1 and CXCR1 form a canonical neutrophil chemoattractant axis; CCL7 is a monocyte/macrophage chemoattractant. CD177 and SELL are neutrophil surface markers, and MMP25 is a neutrophil-specific metalloprotease. The co-occurrence of these genes in the risk group indicates that neutrophil infiltration and degranulation are associated with worse survival in IPF.
- **Evidence strength**: Moderate-high. Multiple independent genes converge on the same program. The GO/KEGG/Reactome annotations are consistent. However, these are bulk-tissue measurements; neutrophil content could reflect cell-composition differences rather than a cell-intrinsic transcriptional program (see Limitations).
- **Limitation**: S100A12 and S100A14 may be expressed in epithelial cells as well as myeloid cells; cell-type deconvolution is needed to confirm the neutrophil attribution.

### Program 2: Epithelial injury, aberrant repair, and growth-factor signaling
- **Direction**: Risk-associated
- **Major supporting genes**: SPP1 (HR 3.40), HTRA1 (HR 4.30), HGF (HR 2.93), MET (HR 2.53), NRG1 (HR 2.76), MUC1 (HR 2.32), KRT17 (HR 2.19), KRT23 (HR 2.59), SPRR1A (HR 2.28), SFTPB (HR 2.66), SFTA2 (HR 2.25), PRSS8 (HR 2.57)
- **Pathway**: Hallmark: Epithelial mesenchymal transition (not directly tested here, but SPP1, KRT17, HTRA1 are recurrent members); Reactome: Signaling by MET; GO: Wound healing
- **Explanation**: SPP1 (osteopontin) is a well-established IPF biomarker associated with fibrosis progression. HTRA1 is a secreted serine protease that degrades extracellular matrix and modulates TGF-β signaling. HGF/MET constitute a growth-factor axis that, while normally pro-repair, can be maladaptive when chronically activated in fibrotic tissue. NRG1 signals through ERBB receptors and is implicated in epithelial proliferation. KRT17 and KRT23 are keratins upregulated in injured/regenerating epithelium; SPRR1A is a cornified envelope gene marking squamous metaplasia—a feature of advanced IPF. SFTPB and SFTA2 are surfactant components whose altered expression reflects alveolar epithelial type II cell dysfunction.
- **Evidence strength**: Moderate-high. The genes span multiple aspects of epithelial injury (keratins, mucins, surfactant) and growth-factor signaling (HGF/MET, NRG1). The network evidence shows STRING-predicted connections among EGFR-related genes (HGF, MET, NRG1, MUC1, EFEMP1), supporting pathway co-membership. However, the direction (risk) is somewhat counterintuitive for HGF/MET given their classical pro-repair roles; the interpretation that chronic activation becomes maladaptive is a supported hypothesis, not established evidence.
- **Limitation**: Bulk tissue cannot distinguish whether these genes reflect epithelial cells, myofibroblasts, or infiltrating cells; spatial transcriptomics would be needed.

### Program 3: Extracellular matrix remodeling and proteolysis
- **Direction**: Risk-associated
- **Major supporting genes**: HTRA1 (HR 4.30), EFEMP1 (HR 2.33), FBLIM1 (HR 2.59), DYSF (HR 3.47), MMP25 (HR 3.26), CHST15 (HR 2.99), HS3ST1 (HR 3.24), TPST1 (HR 2.92), F5 (HR 2.55), SOD3 (HR 2.37)
- **Pathway**: GO: Extracellular matrix organization (Reactome R-HSA-1474244); GO: Extracellular region (CC) was recurrently annotated
- **Explanation**: EFEMP1 (fibulin-3) is a matricellular protein that modulates ECM stiffness and TGF-β signaling. HTRA1 degrades fibronectin and other matrix components. CHST15 and HS3ST1 are sulfotransferases that modify chondroitin sulfate and heparan sulfate, respectively, altering growth-factor sequestration and matrix composition. TPST1 sulfates tyrosine residues on secreted proteins. F5 (coagulation factor V) links the coagulation cascade to fibrosis—a known IPF mechanism. MMP25 is a neutrophil-derived protease. The co-occurrence of matrix proteins, modifying enzymes, and proteases in the risk group suggests that active matrix remodeling—rather than mere fibrosis burden—is associated with mortality.
- **Evidence strength**: Moderate. The genes are functionally coherent, but this program overlaps partially with Programs 1 and 2 (HTRA1, MMP25 appear in multiple programs). The sulfotransferase genes (CHST15, HS3ST1, TPST1) add specificity because they point to glycosaminoglycan modification, which is less commonly highlighted in IPF prognostic studies.
- **Limitation**: The program is broad and may partially reflect the same underlying fibrosis severity rather than a distinct mechanism.

### Program 4: Metabolic reprogramming, redox stress, and metal handling
- **Direction**: Risk-associated
- **Major supporting genes**: SLC7A11 (HR 3.52), SLC39A8 (HR 3.22), STEAP4 (HR 3.03), ACOX2 (HR 3.18), ALDH1A3 (HR 2.27), CYP4F3 (HR 3.78), SLC6A8 (HR 3.21)
- **Pathway**: GO: Cellular response to oxidative stress; KEGG: Ferroptosis (SLC7A11 is a canonical ferroptosis regulator); Reactome: Fatty acid metabolism
- **Explanation**: SLC7A11 (xCT) is the cystine/glutamate antiporter that supports glutathione synthesis and suppresses ferroptosis; its upregulation is often a compensatory antioxidant response. STEAP4 is a metalloreductase involved in iron and copper handling and is induced by inflammatory cytokines. SLC39A8 (ZIP8) imports zinc and manganese and is a known regulator of inflammatory responses. ACOX2 is a peroxisomal acyl-CoA oxidase involved in lipid oxidation. ALDH1A3 and CYP4F3 are involved in retinoid and eicosanoid metabolism, respectively. Together these genes suggest that IPF lungs with poor survival are under metabolic and redox stress, with altered metal handling and lipid oxidation.
- **Evidence strength**: Moderate. The genes are functionally coherent but have not been as extensively studied in IPF as the immune and matrix programs. The ferroptosis connection (SLC7A11) is particularly interesting given recent interest in ferroptosis in fibrosis, but this is an exploratory hypothesis.
- **Limitation**: SLC7A11 upregulation could be a protective compensatory response within the cell even though its expression is associated with worse survival at the tissue level—the direction of effect does not reveal the causal role.

### Program 5: Mucin production and airway/pulmonary epithelial remodeling
- **Direction**: Risk-associated
- **Major supporting genes**: MUC1 (HR 2.32), MUC21 (HR 2.10), CEACAM6 (HR 2.66), CEACAM7 (HR 2.31), AGR3 (HR 2.40), MAL2 (HR 2.44), SUSD2 (HR 2.31), PKP3 (HR 2.50), EMP2 (HR 2.26)
- **Pathway**: GO: O-glycan processing (GALNT14 is also in this program); Reactome: Keratan sulfate/keratinization
- **Explanation**: MUC1 and MUC21 are membrane-tethered mucins; CEACAM6 and CEACAM7 are carcinoembryonic antigen family members involved in cell adhesion and innate immunity. AGR3 is an anterior gradient protein with mucin-associated functions. MAL2 is a lipid-raft adaptor in apical trafficking. PKP3 is a desmosomal plaque protein. The co-occurrence of mucins, CEACAMs, and apical-trafficking genes suggests that aberrant epithelial differentiation toward a mucin-producing/squamous phenotype is associated with worse survival—consistent with the histopathologic observation that honeycombing and bronchiolar metaplasia predict worse outcomes in IPF.
- **Evidence strength**: Moderate. GALNT14 (HR 3.11), a mucin-type O-glycosyltransferase, is an additional supporting gene that strengthens the program. This program partially overlaps with Program 2 (epithelial injury) but is distinct in focusing on the mucin-producing differentiation state rather than general epithelial stress.
- **Limitation**: The program is supported by fewer genes than Programs 1–3 and may be a sub-feature of the broader epithelial injury program.

---

## 3. Key genes and interaction modules

### 1. S100A12
- **Statistical direction**: Risk-associated (HR 2.53, FDR 5.5e-06)
- **Role**: Central node in the neutrophil/innate immune program. S100A12 is a DAMP that binds AGER (RAGE) and TLR4, activating NF-κB (Reactome: TAK1-dependent IKK and NF-κB activation, R-HSA-445989).
- **Gene-gene relationships**: STRING predicts high-confidence interactions with AGER (0.999), S100A8 (0.995), TLR4 (0.970), and S100A9 (0.940). These are predicted physical/binding interactions from STRING, not direct experimental evidence from this dataset. S100A12, S100A8, and S100A9 are co-members of the S100 family and can form heterodimers, but this specific interaction was not experimentally validated here.
- **Evidence type**: Direct (uploaded HR), pathway (Reactome, QuickGO), network (STRING predicted), literature (S100A12 is a known IPF biomarker).

### 2. SPP1 (osteopontin)
- **Statistical direction**: Risk-associated (HR 3.40, FDR 3.99e-05)
- **Role**: Links the immune and matrix programs. SPP1 is a secreted matricellular cytokine that promotes macrophage recruitment, fibroblast activation, and ECM deposition.
- **Gene-gene relationships**: STRING places SPP1 in a module with CD44 (SELL, SLC7A11, SPP1) and with FN1 (CEACAM6, HGF, SPP1). These are predicted network connections (co-membership/co-expression-based), not direct physical interactions validated in this dataset. SPP1-CD44 binding is a well-documented physical interaction in the literature, but that evidence is external to this dataset.
- **Evidence type**: Direct (uploaded HR), network (STRING), literature (SPP1 is among the most replicated IPF prognostic biomarkers).

### 3. HTRA1
- **Statistical direction**: Risk-associated (HR 4.30, FDR 2.57e-06)—the highest HR among well-annotated genes
- **Role**: Secreted serine protease that degrades ECM components and modulates TGF-β/BMP signaling. Bridges the matrix-remodeling and epithelial-repair programs.
- **Gene-gene relationships**: No high-confidence STRING module was retrieved for HTRA1 in this analysis; its relationships are primarily pathway co-membership (ECM organization, proteolysis) rather than direct interactions.
- **Evidence type**: Direct (uploaded HR), pathway (Reactome/GO), literature (HTRA1 is implicated in IPF and other fibrotic diseases).

### 4. HGF/MET module
- **Statistical direction**: Both risk-associated (HGF HR 2.93; MET HR 2.53)
- **Role**: Canonical ligand-receptor pair. HGF binding to MET activates PI3K/AKT and MAPK signaling, promoting epithelial proliferation and survival. In IPF, chronic HGF/MET activation is thought to contribute to aberrant epithelial repair and possibly fibroblast survival.
- **Gene-gene relationships**: HGF-MET is a **direct physical ligand-receptor interaction** (well-established in the literature and captured in STRING/Reactome). SPRY2 (HR 3.26) is a negative regulator of receptor tyrosine kinase signaling, including MET; STRING places SPRY2 and MET in a module with CBL (an E3 ubiquitin ligase that downregulates MET). These are regulatory interactions (SPRY2 and CBL negatively regulate MET signaling), not direct binding partners in the same complex.
- **Evidence type**: Direct (uploaded HRs), pathway (Reactome: MET signaling), network (STRING: CBL-MET-SPRY2), literature.

### 5. MERTK
- **Statistical direction**: Risk-associated (HR 3.70, FDR 1.05e-05)
- **Role**: TAM receptor tyrosine kinase involved in efferocytosis (clearance of apoptotic cells) and macrophage polarization. In IPF, MERTK signaling on macrophages is implicated in the fibrotic response.
- **Gene-gene relationships**: No specific STRING module retrieved here. MERTK's role is inferred from its known biology (efferocytosis, macrophage function) and pathway annotations, not from direct interaction evidence in this dataset.
- **Evidence type**: Direct (uploaded HR), literature (MERTK is a known IPF candidate), pathway.

### 6. SLC7A11
- **Statistical direction**: Risk-associated (HR 3.52, FDR 1.09e-05)
- **Role**: Cystine/glutamate antiporter; rate-limiting for glutathione synthesis and a master regulator of ferroptosis. Its upregulation suggests oxidative stress and potential ferroptosis resistance in the fibrotic lung.
- **Gene-gene relationships**: STRING places SLC7A11 in a module with CD44 and SPP1. The SLC7A11-CD44 interaction is relevant because CD44 is a known regulator of xCT (SLC7A11) surface expression; this is a regulatory interaction documented in the literature, but the STRING edge alone does not establish the mechanism.
- **Evidence type**: Direct (uploaded HR), pathway (ferroptosis, oxidative stress), network (STRING).

### 7. MUC1/CEACAM6/CEACAM7 module
- **Statistical direction**: MUC1 HR 2.32; CEACAM6 HR 2.66; CEACAM7 HR 2.31—all risk-associated
- **Role**: Mucin and CEACAM family members mark aberrant epithelial differentiation (mucinous/squamous metaplasia) and contribute to innate immune signaling at mucosal surfaces.
- **Gene-gene relationships**: CEACAM6 and CEACAM7 are co-members of the CEACAM family and can form heterophilic interactions; they are also co-expressed in epithelial tissues. STRING places CEACAM6 in a module with FN1, HGF, and SPP1. These are pathway co-membership/co-expression relationships; direct physical interaction between MUC1 and CEACAM6 is not established by this dataset.
- **Evidence type**: Direct (uploaded HRs), expression/tissue evidence, literature.

### 8. CXCL1/CXCR1 module
- **Statistical direction**: CXCL1 HR 2.99; CXCR1 HR 3.28—both risk-associated
- **Role**: CXCL1 is a neutrophil chemoattractant; CXCR1 is its receptor on neutrophils. This ligand-receptor pair is the core of the neutrophil recruitment program.
- **Gene-gene relationships**: CXCL1-CXCR1 is a **direct physical ligand-receptor interaction** (canonical chemokine biology). STRING also places CXCL1, CXCL14, and CXCR1 in a module with CXCL5/CXCL6 (via CCL7, CXCL1, CXCR1), supporting chemokine-family co-membership.
- **Evidence type**: Direct (uploaded HRs), pathway (KEGG: Chemokine signaling), network (STRING), literature.

### 9. NRG1
- **Statistical direction**: Risk-associated (HR 2.76, FDR 6.85e-06)
- **Role**: Neuregulin ligand for ERBB receptors; promotes epithelial proliferation and has been implicated in lung development and repair. Its upregulation in IPF suggests aberrant growth-factor signaling.
- **Gene-gene relationships**: STRING places NRG1 in the EGFR-related module (EFEMP1, HGF, MET, MUC1, NRG1). NRG1-ERBB is a direct ligand-receptor interaction, but ERBB receptors were not in the uploaded gene list, so this relationship is inferred from external knowledge.
- **Evidence type**: Direct (uploaded HR), network (STRING), literature.

### 10. CHST15/HS3ST1/TPST1 sulfation module
- **Statistical direction**: CHST15 HR 2.99; HS3ST1 HR 3.24; TPST1 HR 2.92—all risk-associated
- **Role**: Sulfotransferases that modify glycosaminoglycans (CHST15: chondroitin sulfate; HS3ST1: heparan sulfate) and protein tyrosine residues (TPST1). These modifications alter growth-factor binding, matrix stiffness, and cell signaling.
- **Gene-gene relationships**: These genes are not known to physically interact with each other; they are **pathway co-members** in the broader ECM/glycosaminoglycan modification program. Their co-occurrence in the risk group suggests a coordinated sulfation signature, but this is a co-expression/pathway-level inference, not a direct interaction.
- **Evidence type**: Direct (uploaded HRs), pathway (GO: glycosaminoglycan metabolic process), literature (CHST15 is an emerging IPF target).

---

## 4. Validation priorities

### Priority 1: Cell-type deconvolution of the neutrophil/innate immune signal
- **Classification**: Confounding or composition check
- **Why**: The S100A12/CXCL1/CXCR1/CD177/SELL cluster may reflect neutrophil abundance rather than a cell-intrinsic transcriptional program. Bulk lung tissue in IPF contains variable inflammatory infiltrates.
- **Current evidence**: Direct HRs for S100A12 (2.53), CXCL1 (2.99), CXCR1 (3.28), CD177 (2.72), SELL (2.37). GO: Neutrophil migration and KEGG: Chemokine signaling were recurrent annotations.
- **External evidence**: Neutrophilia and neutrophil elastase are established features of IPF; S100A12 is a known IPF biomarker. However, bulk-tissue studies cannot separate cell abundance from per-cell expression.
- **Next step**: Perform single-cell RNA-seq or digital cytometry (CIBERSORTx, BisqueRNA) on the same cohort to determine whether the risk signal is driven by neutrophil proportion or by cell-intrinsic upregulation.
- **Conclusion status**: **Supported hypothesis** (that neutrophil biology is risk-associated), with the cell-composition caveat unresolved.

### Priority 2: Functional validation of HTRA1 in IPF progression
- **Classification**: Mechanistic hypothesis
- **Why**: HTRA1 has the highest HR (4.30) among well-annotated genes and sits at the intersection of matrix remodeling and TGF-β signaling—both central to IPF.
- **Current evidence**: Direct HR 4.30 (FDR 2.57e-06). No independent cohort statistic is available.
- **External evidence**: HTRA1 is implicated in other fibrotic diseases and in IPF by prior literature, but the direction of effect in IPF is not uniformly established.
- **Next step**: In vitro assays with IPF fibroblasts or epithelial cells (HTRA1 knockdown/overexpression; measure collagen deposition, TGF-β pathway activity, migration) followed by a bleomycin model with conditional HTRA1 deletion.
- **Conclusion status**: **Exploratory hypothesis**—the association is strong, but causality is untested.

### Priority 3: SPP1 as a prognostic biomarker for IPF mortality
- **Classification**: Biomarker
- **Why**: SPP1 (osteopontin) is one of the most replicated IPF biomarkers in the literature; its validation in this cohort would strengthen the clinical utility of a multi-gene prognostic signature.
- **Current evidence**: Direct HR 3.40 (FDR 3.99e-05). STRING places SPP1 in modules with CD44 and FN1.
- **External evidence**: SPP1 is widely reported as elevated in IPF plasma and lung tissue and is associated with worse outcomes in multiple cohorts; however, **external statistical validation was not performed** in this analysis—the literature support is contextual, not a replication statistic from this cohort.
- **Next step**: Measure plasma SPP1 in the same cohort and test for association with mortality in a multivariable model adjusted for age, sex, FVC, and DLCO; then test in an independent IPF cohort.
- **Conclusion status**: **Supported hypothesis** for the association; the biomarker utility requires independent validation.

### Priority 4: Testing the ferroptosis/redox hypothesis via SLC7A11
- **Classification**: Mechanistic hypothesis
- **Why**: SLC7A11 (HR 3.52) is a master regulator of ferroptosis, and ferroptosis is an emerging mechanism in fibrosis. If confirmed, this could open a new therapeutic axis.
- **Current evidence**: Direct HR 3.52 (FDR 1.09e-05). STRING places SLC7A11 in a module with CD44 and SPP1.
- **External evidence**: Ferroptosis has been implicated in IPF by recent studies; SLC7A11 expression is regulated by NRF2, which is activated in IPF. However, the direction of the association (high SLC7A11 → worse survival) could reflect either a compensatory antioxidant response or a pro-fibrotic metabolic state—both are plausible.
- **Next step**: Measure lipid peroxidation markers (4-HNE, MDA) and glutathione levels in the same tissue; test SLC7A11 inhibition (e.g., erastin, sulfasalazine) in IPF fibroblast or organoid models.
- **Conclusion status**: **Exploratory hypothesis**—the association is clear, but the mechanism and direction of causality are unresolved.

### Priority 5: Independent-cohort replication of the multi-gene risk signature
- **Classification**: Biomarker (prognostic signature validation)
- **Why**: All 100 genes pass FDR ≤ 0.01 in this cohort, but no independent cohort statistic is available. Without replication, the risk of overfitting or cohort-specific artifacts remains.
- **Current evidence**: Direct HRs for 93 risk-associated genes. The statistical ledger shows 29 duplicated probes/rows, which need to be resolved before signature construction.
- **External evidence**: No independent cohort statistic was supplied; **external statistical validation was not performed**. Literature support for individual genes (SPP1, S100A12, MUC1) does not constitute cohort replication.
- **Next step**: Test a compact risk signature (e.g., HTRA1, SPP1, S100A12, MERTK, MUC1) in an independent IPF cohort with mortality follow-up (e.g., a published IPF transcriptomic cohort with survival data). Use the same HR model and report the concordance statistic.
- **Conclusion status**: **Exploratory hypothesis** for the multi-gene signature; requires independent validation.

---

## 5. Evidence grounding

| Claim | Direct (uploaded) | Pathway/Ontology | Network (STRING) | Disease literature | Independent cohort |
|---|---|---|---|---|---|
| Neutrophil/innate immune program is risk-associated | Yes (S100A12, CXCL1, CXCR1, CD177, SELL, MMP25) | Yes (GO: Neutrophil migration; KEGG: Chemokine signaling) | Yes (S100A12-AGER/TLR4; CXCL1-CXCR1) | Yes (S100A12, neutrophil markers in IPF) | **Not performed** |
| Epithelial injury/aberrant repair is risk-associated | Yes (SPP1, HTRA1, HGF, MET, NRG1, KRT17, KRT23, MUC1) | Yes (Reactome: MET signaling; Hallmark EMT components) | Yes (EGFR-related module) | Yes (SPP1, MUC1, KRT17 in IPF) | **Not performed** |
| Matrix remodeling is risk-associated | Yes (EFEMP1, HTRA1, FBLIM1, CHST15, HS3ST1, TPST1) | Yes (GO: ECM organization) | Partial (modules less clear) | Yes (EFEMP1, CHST15 in fibrosis) | **Not performed** |
| Metabolic/redox stress is risk-associated | Yes (SLC7A11, SLC39A8, STEAP4, ACOX2) | Yes (GO: oxidative stress; KEGG: ferroptosis) | Partial (SLC7A11-CD44) | Emerging (ferroptosis in IPF) | **Not performed** |
| Mucin/epithelial differentiation program is risk-associated | Yes (MUC1, MUC21, CEACAM6, CEACAM7, GALNT14) | Yes (GO: O-glycan processing) | Partial (CEACAM6-FN1 module) | Yes (MUC1 in IPF) | **Not performed** |

**Independence caveat**: The pathway/ontology annotations (QuickGO, Reactome, KEGG) and the STRING network predictions are not independent of each other—both derive from overlapping databases and publications. Similarly, the disease-literature support for individual genes (SPP1, S100A12, MUC1) is contextual and does not constitute an independent replication of the survival association. The only direct statistical evidence is the uploaded HR/P/FDR table.

---

## 6. Limitations and alternative explanations

### 1. Tissue and cell-composition differences
The uploaded data are from bulk lung tissue. IPF lungs contain variable proportions of fibroblasts, myofibroblasts, alveolar epithelial cells, macrophages, neutrophils, and lymphocytes. The neutrophil-related risk signal (S100A12, CXCR1, CD177, SELL) could reflect higher neutrophil content in the lungs of patients who die sooner, rather than a cell-intrinsic transcriptional program. Similarly, the mucin/keratin signal (MUC1, KRT17, SPRR1A) could reflect the extent of honeycombing and squamous metaplasia. **Investigation**: Single-cell RNA-seq, spatial transcriptomics, or digital cytometry on the same samples; correlate gene expression with histopathologic scoring.

### 2. Degenerate or extreme HR values
Several genes show HR values that are biologically implausible: MIR221 (HR 1.93e-22), IHH (HR 1.93e-22), HCN4 (HR 1.93e+21), CONTROL_A_33_P3222196 (HR 5.18e+21), and similar extreme values. These likely reflect near-zero variance, low expression, or technical artifacts (e.g., probes with very low detection rates causing unstable Cox model estimates). The statistical ledger flags XLOC_003303 as having a direction conflict across duplicate rows. These genes should be **excluded or down-weighted** in any downstream signature. The protective-associated direction (7 genes) is dominated by these extreme-value genes and should not be interpreted as a genuine protective program.

### 3. Duplicate probes and unannotated features
The ledger reports 29 duplicated genes/probes and multiple unannotated features (CONTROL_A_33_*, XLOC_*, lincRNA:chr*, LOC*, AK*, BX*). These duplicates can inflate the apparent number of independent genes. The presence of unannotated features with extreme HRs suggests possible alignment or annotation issues. **Investigation**: Collapse duplicates to the gene level using the most stable probe (highest mean expression, lowest variance); manually review unannotated features for genomic location and potential artifacts.

### 4. Disease severity and treatment exposure as confounders
IPF mortality is strongly predicted by baseline lung function (FVC, DLCO), age, sex, and the presence of comorbidities. If the gene expression values correlate with disease severity at the time of sampling, the HRs may partly reflect the severity distribution rather than an independent prognostic effect of the genes. Treatment exposure (antifibrotics: pirfenidone, nintedanib; immunosuppressants; corticosteroids) can also alter gene expression. **Investigation**: Multivariable Cox models adjusting for FVC, DLCO, age, sex, and treatment; test for interaction between gene expression and treatment.

### 5. Association-versus-causation ambiguity
All conclusions here are associations between gene expression and mortality. A gene can be upregulated as a consequence of the disease process (reactive), as a driver of progression (causal), or as a marker of a specific cell type whose abundance is prognostic. The uploaded data cannot distinguish these. For example, HGF upregulation in IPF could be a failed repair attempt (protective but insufficient), a driver of fibroblast survival (pathogenic), or an epiphenomenon of epithelial injury. **Investigation**: Loss- and gain-of-function studies in relevant cell types; Mendelian randomization using eQTL variants that proxy gene expression to test causal effects on IPF risk or progression.

---

**Summary statement**: The uploaded survival analysis provides strong direct statistical evidence that a coordinated risk-associated transcriptomic program—spanning neutrophil-driven innate immunity, epithelial injury and aberrant repair, matrix remodeling, metabolic/redox stress, and mucinous epithelial differentiation—is associated with all-cause mortality in IPF lung tissue, but the protective-associated signal is dominated by technically suspicious extreme HR values, no independent-cohort replication was performed, and the causal versus reactive nature of these associations remains to be established through mechanistic and cell-resolved validation studies.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=65, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 77/100 selected items (partially returned; some queries failed); cbioportal 78/100 selected items (records returned); chembl 13/100 selected items (partially returned; some queries failed); civic 8/100 selected items (records returned); clinicaltrials 48/100 selected items (records returned); clinvar 78/100 selected items (records returned); ensembl 25/100 selected items (partially returned; some queries failed); europepmc 860 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 78/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 81/100 selected items (partially returned; some queries failed); mygene 91/100 selected items (records returned); omnipath 47/100 selected items (records returned); opentargets 80/100 selected items (partially returned; some queries failed); pubmed 658 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 83/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 84/100 selected items (records returned)
Local databases: gutmgene 3/100 selected items (records returned); hmdb 32/100 selected items (records returned); string 79/100 selected items (records returned); trrust 25/100 selected items (records returned)
